SEC Form 4 · accession 0000899243-15-008131
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glynn Wilson
Director
Period of report
Feb 16, 2011
Accepted (ET)
Nov 13, 2015 · 4:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 26, 2014 | J | 513,319 | $0.80 | A | 525,457 | D | |
| Common StockF2 | Dec 2, 2014 | A | 120,000 | $1.00 | A | 645,457 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to BuyF3,F4 | $17.00 | Feb 16, 2011 | A | 1,600 | A | Feb 16, 2011 | Feb 16, 2021 | Common Stock | 1,600 | 38,000 | D |
Explanation of responses
- F1Represents common shares issued by the Company in exchange for cancellation of amounts owed to Dr. Wilson of $410,655 in connection with the Company's restructuring in early 2014 in which Series A preferred was issued for the debt and subsequently converted into the common stock.
- F2Represents shares issued by the Company to Dr. Wilson in satisfaction of compensation owed to Dr. Wilson in the amount of $120,000.
- F3These options were originally issued prior to the Company's most recent February 2014 1 for 100 reverse split and amounts reflected are on a post-split basis. The shares have vested.
- F4Represent current derivative securities owned including the instant award reported hereby.